Faraz Kazmi

1.1k citations

17 papers · 591 indexed · h-index 10

Co-authors: Andrew Parkinson David B. Buckley Phyllis Yerino Brian W. Ogilvie Brandy L. Paris Chad Pope Ryan S. Funk Paul Toren
Topics: Pharmacogenetics and Drug Metabolism (11 papers)Drug Transport and Resistance Mechanisms (5 papers)Biochemical and Molecular Research (4 papers)
Cited by: Pharmacology Physiology Oncology
Journals: Journal of Medicinal Chemistry Drug Metabolism and Disposition Bioorganic & Medicinal Chemistry Letters
Partner nations: United States Belgium Italy

In The Last Decade

Faraz Kazmi

17 papers receiving 560 citations

Peers

Countries citing papers authored by Faraz Kazmi

Since Specialization

Citations

This map shows the geographic impact of Faraz Kazmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faraz Kazmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faraz Kazmi more than expected).

Fields of papers citing papers by Faraz Kazmi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Faraz Kazmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faraz Kazmi. The network helps show where Faraz Kazmi may publish in the future.

Co-authorship network of co-authors of Faraz Kazmi

This figure shows the co-authorship network connecting the top 25 collaborators of Faraz Kazmi. A scholar is included among the top collaborators of Faraz Kazmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faraz Kazmi. Faraz Kazmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Discovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors 2024 ·ACS Medicinal Chemistry Letters ·(unknown),E. Christine Pietsch,Justin S. Cisar,Edgar Jacoby,Faraz Kazmi,Rosalie Matico,P.L. Shaffer,(unknown),Weixue Wang,Ricardo M. Attar,James P. Edwards,Scott D. Kuduk	1
2	Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML 2024 ·Journal of Medicinal Chemistry ·(unknown),Zhuming Zhang,(unknown),Justin S. Cisar,Xiaochun Zhang,Weixue Wang,(unknown),Rosalie Matico,P.L. Shaffer,Edgar Jacoby,Faraz Kazmi,(unknown),Tammy L. Bush,Aaron Patrick,Ulrike Philippar,Ricardo M. Attar,James P. Edwards,Scott D. Kuduk	2
3	N-Heterocyclic 3-Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia 2022 ·Journal of Medicinal Chemistry ·Justin S. Cisar,(unknown),(unknown),Edgar Jacoby,Faraz Kazmi,(unknown),(unknown),Rosalie Matico,P.L. Shaffer,(unknown),(unknown),Chaoyuan Wang,Weixue Wang,Ricardo M. Attar,James P. Edwards,Scott D. Kuduk	12
4	A carboxylic acid isostere screen of the DHODH inhibitor Brequinar 2020 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),E. Christine Pietsch,(unknown),P.L. Shaffer,Edgar Jacoby,Weixue Wang,Faraz Kazmi,Xiaochun Zhang,Ricardo M. Attar,James P. Edwards,Scott D. Kuduk	7
5	An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides 2018 ·Drug Metabolism and Disposition ·Faraz Kazmi,Phyllis Yerino,(unknown),Andrew Parkinson,David B. Buckley,Brian W. Ogilvie	18
6	Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions 2018 ·Drug Metabolism and Disposition ·Faraz Kazmi,Carlo Sensenhauser,(unknown)	8
7	The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments 2015 ·Drug Metabolism and Disposition ·L. Haupt,Faraz Kazmi,Brian W. Ogilvie,David B. Buckley,Brian D. Smith,Sarah Leatherman,Brandy L. Paris,(unknown),Andrew Parkinson	50
8	A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement 2015 ·Drug Metabolism and Disposition ·Faraz Kazmi,(unknown),Phyllis Yerino,Andrew Parkinson	37
9	Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor 2015 ·Drug Metabolism and Disposition ·Faraz Kazmi,Phyllis Yerino,(unknown),Andrew Parkinson	24
10	In vitroinhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential 2014 ·Xenobiotica ·Faraz Kazmi,L. Haupt,(unknown),Brian D. Smith,David B. Buckley,Eric A. Wachter,(unknown)	5
11	Anti-CD28 Monoclonal Antibody–Stimulated Cytokines Released from Blood Suppress CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes In Vitro 2014 ·Drug Metabolism and Disposition ·Maciej Czerwiński,Faraz Kazmi,Andrew Parkinson,David B. Buckley	6
12	Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone Intermediate 2013 ·Drug Metabolism and Disposition ·(unknown),Faraz Kazmi,Andrew Parkinson,David B. Buckley	28
13	Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells) 2013 ·Drug Metabolism and Disposition ·Faraz Kazmi,(unknown),Chad Pope,Ryan S. Funk,(unknown),David B. Buckley,Andrew Parkinson	188
14	High-Resolution Mass Spectrometry Elucidates Metabonate (False Metabolite) Formation from Alkylamine Drugs during In Vitro Metabolite Profiling 2012 ·Drug Metabolism and Disposition ·(unknown),Faraz Kazmi,(unknown),Paul Toren,Andrew Parkinson	9
15	The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel 2011 ·Drug Metabolism and Disposition ·Brian W. Ogilvie,Phyllis Yerino,Faraz Kazmi,David B. Buckley,Amin Rostami‐Hodjegan,Brandy L. Paris,Paul Toren,Andrew Parkinson	79
16	An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes 2011 ·Drug Metabolism and Disposition ·Andrew Parkinson,Faraz Kazmi,David B. Buckley,Phyllis Yerino,Brandy L. Paris,(unknown),Paul Toren,(unknown),Brian W. Ogilvie	58
17	System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes 2010 ·Drug Metabolism and Pharmacokinetics ·Andrew Parkinson,Faraz Kazmi,David B. Buckley,Phyllis Yerino,Brian W. Ogilvie,Brandy L. Paris	59

About Faraz Kazmi

Faraz Kazmi is a scholar working on Pharmacology, Transplantation and Toxicology, having authored 17 papers that have together received 591 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (5 papers) and Biochemical and Molecular Research (4 papers). The work is most often cited by research in Pharmacology (246 citations), Physiology (28 citations) and Oncology (156 citations). Faraz Kazmi has collaborated with scholars based in United States, Belgium and Italy. Frequent co-authors include Andrew Parkinson, David B. Buckley, Phyllis Yerino, Brian W. Ogilvie, Brandy L. Paris, Chad Pope, Ryan S. Funk, Paul Toren, Amin Rostami‐Hodjegan and L. Haupt. Their work appears in journals such as Journal of Medicinal Chemistry, Drug Metabolism and Disposition and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact